NfL
GFAP
Optical coherence tomography (OCT)
Immune profiling and PRLs
Eye-movement biomarkers
Read More
Latest News
CLINICAL CASES IN MS: A PATIENT WITH WORSENING FATIGUE AND NEW MOBILITY PROBLEMS
March 13, 2025Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
D.C. is a 41-year-old woman diagnosed with multiple sclerosis 14 years ago. She was treated initially with a beta interferon. She experienced ongoing disease activity and was transitioned to natalizumab 10 years ago. She was completely stable for six years. She was switched to fingolimod after a significant change in JCV index. She had no MRI changes on natalizumab and a few new MRI lesions on fingolimod. She had no new lesions while on natalizumab and few MRI changes on fingolimod. Her EDSS score a year ago was 1.5 (vision 1, sensory 1, bladder 1). Read More
ACTRIMS Forum 2025 highlights – Focus on ofatumumab
March 10, 2025ACTRIMS Forum 2025 Highlights – Saturday, March 1, 2025
March 1, 2025The following summarizes some of the highlights from Day 2 if the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2025.